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Abstract Ablation of atrial fibrillation is an established
treatment for the management of patients with paroxysmal
and persistent atrial fibrillation. The complex pathophysiol-
ogy of persistent atrial fibrillation has fuelled the concept of
adjunctive substrate modification on top of pulmonary vein
isolation. However, recent studies have failed to demon-
strate additive benefit from complex ablation approaches,
thus supporting that standalone pulmonary vein isolation
may prove sufficient, at least as the initial ablation strategy
in persistent atrial fibrillation. In this premise, the new-gen-
eration cryoballoon is an attractive option in this demanding
subgroup of patients due to its reliable efficacy in achieving
pulmonary vein isolation combined with collateral debulk-
ing of the neighbouring atrial myocardium. In this review,
we present a critical appraisal of the role of cryoablation in
patients with persistent atrial fibrillation, discussing related
technical considerations and existing scientific evidence.
Keywords Persistent atrial fibrillation · Cryoballoon ·
Ablation
Introduction
Atrial fibrillation (AF) is the most common sustained car-
diac arrhythmia and a major public health issue due to its
increasing prevalence and its independent detrimental im-
pact on patients’ quality of life and prognosis [1]. Based
on data from the Framingham study, individuals older than
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40 years, of both genders, have a 1 in 4 lifetime risk of
developing AF [1]. The global prevalence of AF presents
a rising trend mainly due to population ageing [2]. The pro-
jected burden of AF is estimated to increase substantially
to more than double in the European Union from 2010 to
2060, with a profound effect on public health and health
economics [3]. Therefore, optimisation of patient manage-
ment and implementation of measures that may delay or
prevent the natural course of this arrhythmia is of pivotal
importance.
Atrial fibrillation has a rather predicted natural course
characterised by an episodic pattern of increasing fre-
quency and duration with time. The latest ESC and
AHA/ACC/HRS guidelines have proposed classification
of AF into paroxysmal, persistent and long-standing persis-
tent types (Tab. 1; [4, 5]). The major difference is that the
AHA/ACC/HRS guidelines rely solely on episode dura-
tion for AF classification irrespective of whether the index
episode is terminated spontaneously or by intervention. On
the other hand, the ESC guidelines categorise every AF
episode terminated by cardioversion as persistent even if
its duration is limited.
Paroxysmal vs. persistent AF: pathophysiology
and treatment practice
Paroxysmal AF differs from persistent AF not only in the
duration of the arrhythmic episodes but also in the under-
lying mechanisms as well as the type and success rate of
implemented ablation strategies. Paroxysmal AF is mainly
associated with focal triggers or local reentries within or at
the ostia of the pulmonary veins (PVs) [6, 7]. Therefore,
the PVs traditionally constitute the only target of catheter
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Tab. 1 Definition of paroxysmal, persistent and long-standing persistent atrial fibrillation based on the latest European and US guidelines
ESC guidelines AHA/ACC/HRS guidelines
Paroxysmal Self-terminating episode, usually within 48 h but
may last up to 7 days
Episode that terminates spontaneously or with intervention
within 7 days of onset
Persistent Episode lasting longer than 7 days or terminated
by cardioversion
Continuous episode that is sustained longer than 7 days
Long-standing persistent Episode lasting longer than one year Continuous episode lasting more than 12 months
ing the intra-PV origin of the focal trigger, followed by
segmental and currently by circumferential ablation at the
antral level with verification of electrical isolation of all
PVs [8, 9]. PV isolation can be achieved by different en-
ergy sources, the most widely used being cryoenergy and
radiofrequency energy [9–11]. The FIRE and ICE trial, the
largest randomised trial to compare the efficacy and safety
of cryoballoon ablation and point-by-point radiofrequency
current ablation in patients with paroxysmal AF, has been
published recently [12]. Based on the study findings, PV
isolation by cryoballoon ablation is associated with sim-
ilar efficacy and safety as compared with radiofrequency
ablation in paroxysmal AF patients [12].
The pathophysiology of persistent AF is shifted progres-
sively from the PVs (triggers) to the atrial myocardium
(substrate) through a complex process involving diverse
mechanisms such as electrical, structural remodelling and
atrial fibrosis [13]. This mechanistic insight, in conjunction
with the suboptimal efficacy of PV isolation (PVI) alone
in persistent AF ablation, provided the concept of substrate
modification as an additive ablation technique [9, 14]. Sev-
eral adjunctive ablation targets have been proposed, includ-
ing linear lesions [15], complex fractionated atrial electro-
grams (CFAEs) [16], stable rotors or focal sources [17],
low-voltage areas in the left atrium [18], sites of high dom-
inant frequency [19], and ganglionated plexi [20]. Interest-
ingly, the HRS/EHRA/ECAS expert consensus statement
on catheter ablation of AF recommends a more extensive
ablation including linear lesions and complex fractionated
electrograms when treating patients with long-standing per-
sistent AF [9]. However, it should be emphasised that this
consensus recommendation is not based on solid evidence,
since the pertinent trials are limited mainly by a small sam-
ple size [15, 21, 22]. Interestingly, a recently published sur-
vey aiming to assess real-world, everyday practice among
30 European centres reported that 67 % of them use only
standalone PVI as a first-ablation technique in persistent
AF patients [23]. This finding shows that the electrophys-
iological community has not yet been persuaded that the
implementation of adjunctive substrate modification on top
of PVI during persistent AF ablation has a favourable im-
pact on patient outcome, with an acceptable risk-to-benefit
ratio.
The practice of standalone PVI for persistent AF ablation
is expected to be further reinforced by the findings of the
STAR-AF 2 trial, the largest ever multicentre study compar-
ing ablation strategies in this type of AF patient population.
STAR-AF 2 randomised 589 patients with persistent AF
(three-quarters in constant AF for more than 6 months) in
a 1:4:4 ratio to PVI, PVI plus CFAE ablation and PVI plus
lines [24]. Apart from the sample size, additional method-
ological strengths of the study should be mentioned. Patient
follow-up was long (18 months) with rigorous rhythm mon-
itoring (systematic weekly transtelephonic monitoring and
in case of symptoms), patients were unaware of the im-
plemented ablation technique and a second procedure was
allowed at 3–6 months but only by repeating the same abla-
tion strategy in which the patient was initially randomised
(avoiding crossover). Furthermore, acute procedural end-
points were achieved at high rates in all ablation groups
(97 % successful PVI, complete conduction block across
both lines in 74 % of patients and inability to eliminate all
CFAEs in only 9 %), suggesting that almost maximal ben-
efit was gained from the adopted ablation techniques. The
percentage of patients free from arrhythmia recurrence was
similar in the three groups (PVI: 59 %, PVI+CFAE: 49 %
and PVI plus lines: 46 %, p = 0.15), without any difference
after two ablation procedures. In addition, fluoroscopy ex-
posure and procedure time were significantly shorter in the
PVI group.
It should be noted that although ablation has earned its
evidence-based credentials for symptomatic improvement
of patients with AF, the results of ongoing trials (CABANA
and EAST trials) are expected to shed light on the potential
effect of this invasive treatment on hard endpoints such as
stroke incidence and mortality [9].
Technical features of cryoballoon
Cryoablation of AF incorporates an expandable balloon-
based catheter system, which is placed at the entrance of
each PV and enables the electrical disconnection between
the PVs and left atrium (Fig. 1). However, the performance
of the first-generation cryoballoon (Medtronic, Inc., Min-
neapolis, MN) was suboptimal since additional focal abla-
tion was necessary in up to one-third of patients in order to
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Fig. 1 Isolation of the left su-
perior pulmonary vein (LSPV)
using the second-generation
cryoballoon in a patient with
persistent atrial fibrillation. a In
the left half of the tracing, there
is 2 to 1 entrance block in the
LSPV (the dotted yellow ovals
demarcate PV potentials). In
the right half of the recording,
the PV potentials disappear,
documenting the achievement
of entrance block. b Plot of
freezing temperature over time
(lesion duration 240 sec). Isola-
tion was achieved in 120 sec at
a temperature of –43 oC, while
the nadir temperature achieved
was –46 oC
Fig. 2 Different generations
of cryoballoons with respective
technical features
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Tab. 2 Cryoablation studies (published as full papers) exclusively in persistent AF patients: methodological characteristics and acute procedural
outcomes








Ciconte et al. [33] 63 28 mm-CB2
(100 %)
87.1± 38.2 14.9± 6.1 100/6.3 First study on persistent AF
No CMAP
Lemes et al. [34] 49 28 mm-CB2
(100 %)
113.6± 33.5 21.3± 6.7 100/0 Post-blanking continuation
of AAD in 33 % of patients
Koektuerk et al. [36] 100 28 mm-CB2
(100 %)
96.2± 21.3 19.7± 6.7 100/3 Bonus 240-sec freeze
post-PVI in all patients
Guhl et al. [37] 69 CB2 (88.4 %) 147± 45 45.0± 20.2 100/9 17 % of AF-free patients at
one year were still on AADs
CMAP in a subset of patients
Ciconte et al. [38] 100a 28 mm-CB2
(100 %)
90.5± 41.7 14.5± 6.6 100/4 First comparison of cryo vs.
RF in persistent AF patients
N number of patients included, PVI pulmonary vein isolation, PNP phrenic nerve palsy, CB2 second-generation cryoballoon, CMAP compound
motor action potential, AAD antiarrhythmic drugs, AF atrial fibrillation, RF radiofrequency
aTotal patient population – 50 patients in the cryoablation group
achieve electrical PVI [25]. This caveat was at least partly
attributed to the inhomogeneous and limited distribution of
the freezing zone only around the equator of the balloon
(Fig. 2; [26]). Therefore, in order to achieve contact of
the freezing zone with the targeted myocardium, the first-
generation cryoballoon had to be placed at the PV ostium
with a strictly coaxial orientation, which proved demanding
especially in peculiar PV anatomies and in the right inferior
PV.
The second-generation cryoballoon, approved by the US
Food and Drug Administration (FDA) in 2012, incorporated
several technical improvements, including eight injection
tubes, compared with four in the first-generation cryobal-
loon, and a more distal location of the injection ports on
the catheter shaft. These modifications enable a larger and
more uniform freezing zone covering the entire northern
hemisphere of the balloon [26]. From a practical perspec-
tive, this cooling feature facilitates the procedure by en-
abling contact of the ice cap with the PV antrum, even
if the catheter balloon shaft is not parallel to the targeted
vein. In addition it enhances proper contact of the ice cap
even if the PV antrum has an uncommon shape. These fea-
tures have increased procedural efficacy and have resulted
in significantly higher freedom from AF recurrence when
using second- as compared with first-generation cryoabla-
tion [27–30]. However, several studies have reported an
increased occurrence rate of phrenic nerve palsy in com-
parison with first-generation cryoballoon, which is possibly
associated to the more extended freezing area of the second
cryoballoon [27].
In May 2015, a third-generation cryoballoon (Arctic
Front Advance® ST) received approval from the FDA for
the treatment of patients with drug refractory, recurrent,
symptomatic, paroxysmal AF. The difference in catheter
design in comparison with the second-generation cryobal-
loon is the 40 % reduction in the length of the catheter tip.
This feature provides improved manoeuvrability and allows
a more proximal retraction of the circular catheter during
ablation and thus a higher rate of real-time PV recordings
[31]. Real-time monitoring of PV potentials is important
to document the time of isolation (time to effect); this
procedural parameter is a predictor of permanent PVI and
should be taken into account to tailor the ablation strategy
and the freeze duration. In a recently reported practice
guide, a reduction of cryolesion duration to 150 seconds is
recommended in case of early time to effect (≤30 sec) [32].
Studies of cryoablation in persistent atrial
fibrillation
Based on the aforementioned ‘less is more’ approach in
persistent AF ablation, PVI may prove to be a sufficient
ablation strategy in persistent AF, since adjunctive substrate
modification seems to provide no additional favourable im-
pact. Therefore, cryoablation of the PVs may also suffice
not only in paroxysmal but also in persistent AF. This hy-
pothesis has been tested in several recent studies (Tab. 2,
Fig. 3).
Ciconte et al. reported the first study of cryoablation in
63 consecutive, prospectively evaluated patients with per-
sistent AF (mean duration of continuous AF persistence
7.2 months) [33]. Acute PVI was achieved in all PVs with
a 28 mm second-generation cryoballoon, without the need
for any additional focal lesions. During ablation, 27 % of
patients with AF at presentation converted to sinus rhythm.
Phrenic nerve palsy occurred in 6.3 % of patients and per-
sisted post-discharge in only one patient. Freedom from any
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Fig. 3 Reported freedom from
atrial fibrillation during a fol-
low-up period of 12 months
following cryoablation of persis-
tent atrial fibrillation (taking into
account a 3-month blanking pe-
riod). The reported percentage
of the study by Koektuerk et al.
pertains to a follow-up period of
10.6 ± 6.3 months
tachyarrhythmia after a single ablation, taking into account
a 3-month blanking period, was 60.3 %. Furthermore, re-
lapses during the blanking period and duration of persistent
AF were independent predictors of arrhythmia recurrence
during follow-up. This last finding argues in favour of ab-
lation at earlier stages in the natural course of persistent
AF.
In a retrospective study of 48 persistent AF patients,
Lemes et al. reported a 100 % acute PVI rate and a 1-
year clinical success rate of 69 % [34]. Bonus cryolesion
after successful PVI was omitted systematically after the
initial minority of patients, in an effort to minimise po-
tential collateral damage of cumulative cryoenergy in the
phrenic nerve and the oesophagus. Furthermore, the com-
bination of intermittent fluoroscopy during freezing, tactile
feedback of diaphragmatic contraction and monitoring of
continuous motor action potential resulted in no phrenic
nerve palsy [35]. Electrical reconnection of previously iso-
lated PVs was documented in the majority of patients with
atrial tachyarrhythmia recurrence.
Koektuerk et al. evaluated the performance of cryoabla-
tion in a cohort of 100 patients with persistent AF (mean
duration 5.5 ± 3.7 months) [36]. In a mean follow-up period
of 10.6 ± 6.3 months, 67 % of patients were free from atrial
tachyarrhythmia recurrence when considering a 3-month
blanking period. Phrenic nerve palsy occurred in three pa-
tients despite recording of diaphragmatic compound motor
action potential during phrenic nerve pacing, but it resolved
during the intervention in two of them. All patients expe-
rienced a significant improvement in their EHRA scores,
irrespective of the ablation outcome, though the magnitude
of symptomatic improvement was significantly increased
among patients without atrial tachyarrhythmia recurrence.
Atrial tachyarrhythmia recurrence during the blanking pe-
riod was the only significant independent predictor of recur-
rence at the end of the follow-up period. In a single-centre,
prospective registry of consecutive persistent AF patients,
Guhl et al. reported a 1-year, single-procedure, atrial ar-
rhythmia recurrence-free rate of 59 %, taking into account
a 3-month blanking period. In this case series the second-
generation cryoballoon was used in 88.4 % of patients and
the reported rate of major complications was 2.8 % [37].
To our knowledge, only one study has compared ra-
diofrequency versus cryoablation exclusively in persistent
AF patients [38]. In this single-centre, non-prospective,
non-randomised study, the single procedural outcome of ra-
diofrequency ablation (using three-dimension mapping and
contact-force ablation catheter) versus cryoablation (28 mm
second-generation cryoballoon) was assessed in a cohort
of 100 patients with symptomatic, drug-refractory, persis-
tent atrial fibrillation (mean duration of longest continuous
time spent in AF 7.2 and 7.6 months respectively). Pro-
cedural duration and fluoroscopy time were significantly
shorter in the cryoablation group. The percentage of pa-
tients free from all documented atrial tachyarrhythmias last-
ing more than 30 sec, without antiarrhythmic drugs and fol-
lowing a single ablation procedure, was similar between the
compared groups after 12 months of follow-up (60 % with
cryoablation versus 56 % with radiofrequency ablation, p =
0.71, when a 3-month blanking period was taken into ac-
count). In multivariate analysis, duration of persistent AF
and relapse during the blanking period were the only sig-
nificant independent predictors of arrhythmia recurrences.
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Tab. 3 Ongoing trials aiming to evaluate the role of catheter ablation with cryoballoon in persistent atrial fibrillation. (ClinicalTrials.gov April
2016)
Name of the trial AF type studied Identifier Status
Cryoballoon Ablation in Patients With Longstanding Persistent
Atrial Fibrillation (CRYO-LPAF)
Longstanding persistent NCT02294929 Recruiting
Persistent Atrial Fibrillation Cryoballoon Ablation (PAFCA) Persistent NCT02166723 Active, not recruiting
A Prospective Study of Medical Therapy Against Cryobal-
loon Ablation in Symptomatic Recent Onset Persistent AF
(METACSA)
Early onset persistent NCT02389218 Not yet recruiting
Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation:




Catheter Ablation Compared With Pharmacological Therapy for
Atrial Fibrillation (CAPTAF)
Paroxysmal/persistent NCT02294955 Active, not recruiting
Cryoballoon Ablation for Early Persistent Atrial Fibrillation
(Cryo4 Persistent AF)
Early persistent NCT02213731 Recruiting
FREEZE Cohort Study Paroxysmal/persistent NCT01360008 Active, not recruiting
Prospective, Randomized Comparison of Hybrid Ablation vs.
Catheter Ablation (PRHACA)
Persistent NCT02344394 Recruiting
Tab. 4 Pros and cons of cryoablation in persistent atrial fibrillation
Advantages
Reliable acute pulmonary vein isolation (PVI) in practically all patients
Efficacy beyond PVI due to extended cooling area in the left atrium with significant posterior wall electrical debulking
Easy-to-use and less cumbersome compared with point-by-point circumferential ablation
No need for three-dimension mapping system
Reduced procedure and fluoroscopy time compared to classical ablation strategies
Disadvantages
Inability to target ad-hoc extra-pulmonary vein triggers or factors contributing to AF maintenance (e. g. rotors, ganglionated plexi), as is the case
especially with redo procedures
Inability for additional substrate modification (if and when needed!)
Difficulties in peculiar anatomies (common trunk, atypical branching patterns)
Inability to ablate ad-hoc atrial macro-reentry tachycardias
Additional catheter needed to perform pacing manoeuvers for ruling out far-field recording of left atrial appendage electrograms in the circular
catheter when targeting the left veins
Potential collateral oesophageal injury
Incidence of phrenic nerve palsy, although reduced when safety precautions implemented
Several ongoing trials are expected to shed further light
in the efficacy and safety of cryoablation in patients with
persistent atrial fibrillation (Tab. 3).
Strengths and limitations of the cryoballoon in
persistent AF ablation
The anatomy of the pulmonary veins presents considerable
variation in shape, size and branching pattern. The existing
discrepancy in the reported PV diameters is attributed to
differences in the imaging modalities used, in the studied
patient populations but mainly to the lack of a practical con-
sensus definition of the level of the antrum, which separates
the PVs from the left atrium [39–42]. A consistent finding
in all studies is the oval shape of the PVs, especially of left
PVs, with the minimal cross-sectional diameter oriented
in the anteroposterior direction [39, 40]. Furthermore, in
a large series of 473 consecutive patients who underwent
contrast-enhanced magnetic resonance imaging of the left
atrium and PVs, the diameters of the PVs were larger in
patients presenting with persistent as compared with parox-
ysmal AF [39]. Even when the highest values of the max-
imal PV diameters among persistent AF patients are taken
into account (ranging from 20.1 to 22.9 mm), they were
considerably less than the critical value of 28 mm, which
is the diameter of the spherically-shaped cryoballoon used
in everyday practice.
Due to this area mismatch between balloon and PVs,
when the cryoballoon is positioned against the PV antrum,
its cooling distal hemisphere comes in contact not only with
the PV antra but also with adjacent atrial myocardial tissue.
It is worth noting that since the anteroposterior diameter of
the veins is typically smaller than their superior-inferior di-
ameter, the collaterally ablated atrial tissue is located mostly
at the posterior and anterior wall. Kenigsberg et al. ele-
gantly calculated the area of the ablated cardiac tissue after
cryoablation of the PVs by performing a post-cryoablation
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electroanatomical voltage map of the left atrium [43]. In to-
tal, only 27 % of the entire left atrial posterior wall surface
area remained electrically intact and unablated following
cryoablation with a 28-mm cryoballoon.
Therefore, it is of primary importance that although the
cryoballoon conceptually only targets the PVs, it addition-
ally performs considerable electrical debulking of the left
atrium. This widely circumferential extension of the cool-
ing area may provide collateral benefit by ablating local
contributors in AF triggering and maintenance such as gan-
glionic plexi and rotors, which may have therapeutic impli-
cations among patients with persistent AF [17, 44, 45].
On the other hand, the inadvertent extension of the cool-
ing area at the posterior wall raises concern regarding poten-
tial collateral damage of the neighbouring oesophagus. The
incidence of induced oesophageal thermal lesions with the
use of the second-generation 28-mm cryoballoon in parox-
ysmal and persistent AF ablation is 12 % and is signifi-
cantly correlated with the lowest endoluminal oesophageal
temperature during each freeze cycle [46]. The interrup-
tion of cryoenergy delivery when the lowest endoluminal
oesophageal temperature reaches a certain cut-off limit has
been proposed as a safety measure to reduce the occurrence
of oesophageal lesions [47]. From a practical viewpoint,
a cut-off oesophageal temperature limit of 15 oC is asso-
ciated with a very low (1.5 %) incidence of oesophageal
injury without impairing the achievement of PVI [47].
A detailed description of the advantages and pitfalls of
using cryoablation for persistent AF ablation is presented
in Tab. 4.
Conclusion
Invasive treatment of persistent AF is a challenging goal
due to its diverse pathophysiology. Until novel mechanistic
insights enable a more tailored and individualised approach
to persistent AF patients, standalone PVI may be sufficient,
at least as the initial invasive ablation strategy. In this line,
the new-generation cryoballoon seems to be an easy-to-use
treatment option, which provides reliable PVI with adjunc-
tive debulking of the neighbouring atrial myocardium. Ac-
cumulating experience and data from upcoming studies is
expected to further elucidate the role of cryoablation in the
management of patients with persistent atrial fibrillation.
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